
Head-to-head TYK2 data show that agents within the same mechanistic class may differ meaningfully in speed, depth of clearance, and target selectivity.

Head-to-head TYK2 data show that agents within the same mechanistic class may differ meaningfully in speed, depth of clearance, and target selectivity.

Two-year icotrokinra data highlight sustained clearance in difficult-to-treat sites and raise important questions about IL-23–mediated disease memory.

Selecting an oral psoriasis therapy requires balancing disease characteristics with efficacy, convenience, comorbidities, and individual patient priorities.

Advances in psoriasis biology are translating key inflammatory pathways into increasingly precise oral treatment targets.

Route of administration is becoming a more balanced decision as newer oral therapies narrow historical differences in treatment efficacy.

Recognizing psoriasis as a systemic disease may help clinicians move appropriate patients beyond repeated topical treatment.

As therapies improve, complete clearance and meaningful quality-of-life gains are increasingly shaping expectations for psoriasis care.

Advances across topical, biologic, and oral therapies are expanding the possibilities for individualized systemic psoriasis care.

From false positives to lost follow-up and unneeded LTBI therapy, experts detail the harms of routine TB testing with IL-17 and IL-23 inhibitors in psoriasis.

The NPF/IPC TB statement isn’t a blanket no-test rule. Experts explain when screening still fits, from endemic regions to JAK inhibitors and other DMARDs.

Experts explain why ustekinumab and TYK2 inhibitors were excluded from new TB testing guidance and how FDA label changes for IL-17/IL-23 agents could happen.

Basic science, trials, real-world data, and FAERS reports show little TB reactivation risk with IL-17 and IL-23 inhibitors, supporting new NPF/IPC guidance.

New NPF/IPC guidance questions routine TB testing for IL-17 and IL-23 inhibitors in psoriasis, a TNF-era practice lacking direct supporting evidence.

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Are IL-23 inhibitors, rather than IL-17 inhibitors, the preferred biologic for psoriasis patients at risk of developing psoriatic arthritis?

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

An expert discusses treatment selection for atopic dermatitis (AD) based on short and long-term data.

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).